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Background: The prognosis for hepatocellular carcinoma (HCC) is dependent upon tumour stage, performance status (PS),
severity of underlying liver disease, and the availability of appropriate therapies. The unavailability of sorafenib may have a
significantly adverse effect on the prognosis of UK patients with advanced HCC. During the study period, access to sorafenib was
at the discretion of local health funding bodies, a process that may delay or deny access to the drug and that remains in place for
Wales, Scotland, and Northern Ireland. Here, we attempt to address the impact of this system on patients with advanced HCC in
the United Kingdom.
Methods: This is a retrospective study performed in the two largest specialist hepatobiliary oncology units in the United Kingdom.
Funding applications were made to local funding bodies for patients with advanced HCC for whom sorafenib was considered
appropriate (advanced HCC not suitable for loco-regional therapies, compensated chronic liver disease, PS 0–2).
Results: A total of 133 applications were made, of which 57 (43%) were approved and 76 (57%) declined. Demographics and
prognostic factors were balanced between the two groups. This cohort had a number of adverse prognostic features: patients
were predominantly PS 1–2; the majority had multifocal disease with the largest lesion being 45 cm; and macroscopic vascular
invasion, metastases, and AFP 41000 ng ml 1, were each present in one-third of cases. The median time from application to
funding decision was 17 days (range 3–260 days). For the primary ‘intention-to-treat’ analysis, median overall survival was
4.1 months when funding was declined, and 9.5 months when funding was approved (hazard ratio (HR) 0.48; 95% CI 0.3186–0.7267;
P¼ 0.0005).
Conclusion: These data support the use of sorafenib for patients with advanced HCC as an effective intervention. In the United
Kingdom, this applies to a relatively small group of patients, estimated to total B800 per year who, unfortunately, do not survive
long enough to themselves lobby for the availability of this drug. These data provide a comparison of sorafenib with supportive
care and demonstrate the potential detrimental impact on patient outcomes of rationing health-care resources on the basis
of cost.
With an estimated 700 000 new cases per year, hepatocellular
carcinoma (HCC) represents the fifth commonest cancer and is the
third leading cause of cancer death worldwide. Although cases
occur predominantly in the Far East and Sub-Saharan Africa, the
incidence is rising in the West, including the United Kingdom,
largely due to an increasing incidence of Hepatitis C virus
infection, alcoholic liver disease, and non-alcoholic steatohepatitis
related to obesity and type II diabetes (El-Serag and Mason, 1999).
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The majority of patients present with disease that is too advanced
for curative surgery by either resection or transplantation.
Randomised phase III placebo-controlled trials have demonstrated
a survival advantage for sorafenib, a small molecule multikinase
inhibitor of the mitogen-activated protein kinase pathway and of
vascular endothelial growth factor receptors, compared to best
supportive care in patients with advanced HCC (Llovet JM et al,
2008; Cheng et al, 2009). On this basis, sorafenib has been
accepted as the standard of care in this context. However, in the
current health economic climate, the potential financial burden of
novel anticancer drugs is of increasing relevance. In England and
Wales, the availability of new drugs is determined by the National
Institute for Health and Clinical Excellence (NICE) and in Scotland
by the Scottish Medicines Consortium (SMC) based on an
assessment of clinical- and cost-effectiveness. Following negative
NICE and SMC appraisals, sorafenib was not routinely available
within the National Health Service (NHS) in the United Kingdom.
Since the prognosis for HCC is dependent upon tumour stage,
performance status (PS), severity of underlying liver disease, and
the availability of appropriate therapies, the unavailability of
sorafenib may have a significantly adverse effect on the prognosis
of UK patients with advanced HCC (Palmer and Johnson, 2006).
During the study period, access to sorafenib was at the
discretion of local health funding bodies through individual
funding requests, a process that may delay or deny access to the
drug, with decisions being made on a case-by-case basis. Here, we
attempt to address the impact of this system on patients with
advanced HCC in the United Kingdom.
PATIENTS AND METHODS
This is a multicentre retrospective study performed at the two
largest specialist hepatobiliary oncology units of the United
Kingdom (Kings College Hospital, London, and Queen Elizabeth
Hospital, Birmingham). Institutional approvals for this study were
obtained. Between July 2007 and May 2009, funding applications
were made to local funding bodies for patients with advanced HCC
for whom sorafenib was considered appropriate (advanced HCC
not suitable for loco-regional therapies, compensated chronic liver
disease and PS 0–2). The primary outcome measure was overall
survival from the date of application. The secondary outcome
measure was overall survival in those receiving at least one dose of
sorafenib.
RESULTS
A total of 133 applications were made to 42 local funding bodies in
England and Wales, of which 57 (43%) were approved and 76
(57%) declined. The criteria for application were uniform across
both Centres and comprised clinical information to indicate that,
in the treating clinician’s opinion, sorafenib was the most
appropriate therapy – that is, it had a good PS (WHO PS 0–2);
well-compensated background chronic liver disease; not a suitable
candidate for loco-regional therapies (surgery, transplantation,
local ablation, and TACE). On this basis, decisions on whether to
fund were not apparently based on clinical variables. Indeed, as
subgroup analyses of the sorafenib-randomised trials indicate
similar benefit across all subgroups, there are no known predictive
variables that the funding bodies could have used to select patients
more likely to benefit from treatment. This is reflected in the key
demographic and prognostic factors, which are summarised in
Table 1. In general, these were balanced between the two groups
and between the two centres, and statistical comparison of each
variable revealed no significant differences. Notably, this cohort
had a number of adverse prognostic features: patients were
predominantly PS 1–2; the majority had multifocal disease with the
largest lesion being 45 cm; and macroscopic vascular invasion,
metastases, and AFP 41000 ng ml 1 were each present in
approximately one-third of cases. The median time from
application to funding decision was 17 days (range 3–260 days).
For the primary ‘intention-to-treat’ analysis, the median overall
survival was 4.1 months when funding was declined, and
9.5 months when funding was approved (hazard ratio (HR) 0.48;
95% CI 0.3186–0.7267; P¼ 0.0005; Figure 1). In 14 of the 57 cases
where funding was approved, in the time awaiting the funding
body decision, the clinical condition deteriorated such that
treatment could not be commenced. The median survival for the
43 patients who received at least one dose of sorafenib was 10.7
months (HR 0.38; 95% CI 0.25–0.59; Po0.0001). In those
receiving sorafenib, the median duration of treatment was 5.1
months. There was a higher proportion of patients with metastatic
disease in the unfunded group, which conceivably could negatively
influence the survival in this group. However, a sensitivity analysis
Table 1. Patient demographics and prognostic factors
Demographic
All
patients
Sorafenib
funded
Sorafenib
not funded
Patient number 133 57 76
Kings patients 71 30 41
Birmingham patients 62 27 35
M : F 108 : 25 52 : 5 56 : 20
Median age (range) 62 (16–86) 61 (16–82) 62 (17–86)
PS 0:1 : 2 (%) 19 : 49 : 32 20 : 48 : 32 18 : 48 : 34
Child–Pugh A 82% 84% 80%
AFP X1000 31% 30% 31%
Multifocal 70% 65% 75%
Largest lesion 45 cm 68% 78% 60%
Macroscopic vascular invasion 34% 41% 29%
Extrahepatic metastases 39% 30% 46%
Abbreviation: PS¼performance status.
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Figure 1. Survival proportions in patients for whom an application
for sorafenib funding was made.
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excluding all patients with metastases did not significantly affect
the data, again indicating that differences in survival are likely due
to treatment effects rather than due to imbalances in prognostic
variables between the two groups (non-metastatic patients, median
survival funded vs unfunded: 8.95 vs 3.7 months; HR 0.51, 95% CI
0.32–0.82; P¼ 0.0061).
Four patients in this series had fibrolamellar variant HCC
(three funding-approved, one declined). It is considered that this
variant may confer a better prognosis than classical HCC, which
may, at least in part, be due to the younger age at presentation
(median 20–30 years) and the absence of underlying cirrhosis.
These factors may permit more radical surgical treatments at
initial presentation, although relapse with metastatic disease is
common. Upon relapse, a variety of treatments including further
surgery and conventional chemotherapy may be employed such
that, by the time sorafenib is considered, prognosis is likely to be
poor. Taking into account a potential confounding influence of
fibrolamellar patients, a further survival analysis excluding these
patients demonstrated the median overall survival of 8.98 and
3.68 months (HR 0.45; 95% CI 0.29–0.69; P¼ 0.0002) in funded
and unfunded cases, respectively, indicating no confounding
influence by these patients.
DISCUSSION
Sorafenib is the first systemic agent to demonstrate a statistically
significant survival benefit in adequately powered, randomised
phase III trials for patients with advanced HCC and is considered
the standard of care in this context. Although these trials
represented patients from Europe and the Far East, our study
suggests a similar benefit for patients in the UK. Notably, these
patients had a number of adverse prognostic features compared
with those recruited to the phase III trials, including poorer PS and
greater tumour burden. Despite this, the survival advantage for
these patients compares favourably to the randomised trials. Of
note, the HR reported here (0.48) is somewhat better than that
reported in the SHARP trial (0.69) (Llovet et al, 2008). This may, in
part, be due to the relatively worse outcome for untreated patients
reflecting a number of adverse prognostic variables present in this
study population and additionally may reflect the experience of
two high-volume liver units and the evolution of experience in
managing toxicities and maintaining dose intensity for sorafenib-
treated patients since the original publication of the trial data.
Although treatment in this study was not randomly assigned, the
funding applications were made using the same criteria for
suitability for sorafenib, and the baseline demographics between
the two groups were generally balanced, suggesting that the
improved outcome was due to a treatment effect rather than due to
confounding prognostic variables.
The SMC and NICE single technology appraisals of sorafenib
for advanced HCC recommended that the drug should not be
available on the basis of cost effectiveness (National Institute for
Health and Clinical Excellence and Scottish Medicines Consortium
websites). This decision was based on a calculated cost per
incremental quality-adjusted life-year (QALY) gain of approxi-
mately d64 000, which exceeds the standard threshold of
approximately d30 000 for drugs used to prolong survival near
the end of life. This calculation was derived using the HR for
overall survival of 0.69 reported in the phase III trials. However,
recalculation of this figure using the HR of 0.48 reported here
reduces the cost per incremental QALY to approximately d30 000.
The data reported here support the use of sorafenib for patients
with advanced HCC as clinical and cost-effective interventions. In
the United Kingdom, this applies to a relatively small group of
patients, estimated to total B800 per year who, unfortunately, do
not survive long enough to themselves lobby for the availability of
this drug.
Our results provide a comparison of sorafenib with supportive
care and demonstrate the potential detrimental impact on patient
outcomes of rationing health-care resources on the basis of cost.
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